<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200721048159N5</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-12-29</date_registration>
      <primary_sponsor>Vice Chancellor for Research and Technology of Lorestan University of Medical Sciences</primary_sponsor>
      <public_title>Antioxidant effects of crocin in patients undergoing angiography</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the Effect of Crocin on Oxidative Stress Biomarkers in Patients under Angiography with Contrast Agents: A Randomized Controlled Clinical Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-09-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/58242</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: Patients will be divided into two groups using the stratified blocked randomization method. In this way, considering the gender (female, male), a stratum will be formed and within this stratum, the samples in the form of four blocks will be randomly assigned to the desired groups.</study_design>
      <phase>3</phase>
      <hc_freetext>contrast induced acute kidney Injury.</hc_freetext>
      <i_freetext>Intervention 1: Control group:  normal saline 1ml/kg from 6 hours before to 6 hours after administration of contrast agent. Intervention 2: Intervention group: normal saline 1ml/kg from 6 hours before to 6 hours after administration of contrast agent + 30mg/day crocina (Two tablets containing 15 mg of purified crocin from Poyesh Sina Pharmaceutical Company ) form the  night before receiving contrast agent to the second night after reviving contrast agent.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Forouzan Ahmadpour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Ayatullah Madani Hospital, Khairabad Street, Shaghayegh Square, Khorramabad, Lorestan</address>
        <city>Khorramabad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6814713115</zip>
        <telephone>+98 66 3341 9123</telephone>
        <email>ahmadpourforoz@yahoo.com</email>
        <affiliation>Khoram-Abad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Forouzan Ahmadpour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Pharmacy, Lorestan University of Medical Sciences, , 3 km of Khorramabad-Tehran Road, Pardis University Complex, Khorramabad, Lorestan</address>
        <city>Khorramabad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6814713115</zip>
        <telephone>+98 66 3341 9123</telephone>
        <email>ahmadpourforoz@yahoo.com</email>
        <affiliation>Khoram-Abad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>patient consent to enter to the study
being candidate for  angiography
being over 18 years old
systolic pressure of greater than 90 mm Hg</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>patient's tendency to exit from the study
having Anaphylactic and anaphylactoid reactions during contrast media administration
consumption of common antioxidant medicines in less than one week before use of contrast media and angiography
consumption of nephrotoxic medicines (aminoglycosides, vancomycin and others) in less than one week before use of contrast media and angiography
unstable kidney status or need of kidney transplantation
impossibility of intravenous hydration for the patient
consumption of Warfarin
pregnancy and breastfeeding
history of hypersensitivity to saffron
history of hypersensitivity to contrast media
participate in other clinical trials  that their results may confound this intervention at least for a 28 days period</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N17.8</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other acute kidney failure</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Control group:  normal saline 1ml/kg from 6 hours before to 6 hours after administration of contrast agent</i_keyword>
      <i_keyword>Intervention group: normal saline 1ml/kg from 6 hours before to 6 hours after administration of contrast agent + 30mg/day crocina (Two tablets containing 15 mg of purified crocin from Poyesh Sina Pharmaceutical Company ) form the  night before receiving contrast agent to the second night after reviving contrast agent</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Serum creatinine. Timepoint: before getting medical regime and 24 and 48 hours after getting contrast media. Method of measurement: patient's medical file.</prim_outcome>
      <prim_outcome>Blood urea nitrogen. Timepoint: Before getting medical regime and 24 and 48 hours after getting contrast media. Method of measurement: Laboratory kit.</prim_outcome>
      <prim_outcome>Superoxide dismutase. Timepoint: Zero hours before getting medical regime of study and 4 hours after getting contrast media. Method of measurement: Laboratory kit.</prim_outcome>
      <prim_outcome>Malondialdehyde. Timepoint: Zero hours before getting medical regime of study and 4 hours after getting contrast media. Method of measurement: Laboratory kit.</prim_outcome>
      <prim_outcome>Catalase. Timepoint: Zero hours before getting medical regime of study and 4 hours after getting contrast media. Method of measurement: Laboratory kit.</prim_outcome>
      <prim_outcome>Glutathione proxidase. Timepoint: Zero hours before getting medical regime of study and 4 hours after getting contrast media. Method of measurement: Laboratory kit.</prim_outcome>
      <prim_outcome>Reactive oxygen species. Timepoint: Zero hours before getting medical regime of study and 4 hours after getting contrast media. Method of measurement: Laboratory kit.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice Chancellor for Research and Technology of Lorestan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-08-17</approval_date>
        <contact_name>Ethics Committe of Lorestan University of Medical Sciences</contact_name>
        <contact_address>Office of Research Ethics Committee, Vice Chancellor for Research and Technology, Lorestan University of Medical Sciences, 3 km of Khorramabad-Tehran Road, Pardis University Complex, Khorramabad, Lorestan Khorramabd Lorestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
